Study ID,Study,Experiment Name,Experiment Notes,Strain Ont ID,Strain,Sex,Age,# of Animals,Sample Notes,Clinical Measurement Ont ID,Phenotype,Formula,Clinical Measurement Notes,Average Type,Value,Units,SEM,SD,Method Ont ID,Method,Method Site,Method Duration,Method Notes,Post Insult Type,Post Insult Time Value,Post Insult Time Unit,Conditions,Record ID,Condition 1,Condition 2,Condition 3 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,56.16,uV,17.2,42.1312,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,30,min,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) ,108452,2-Chloro-5-hydroxyphenylglycine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-4.5 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,381.17,uV,37.99,93.0561,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,30,min,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) ,108453,2-Chloro-5-hydroxyphenylglycine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-2.5 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,440,uV,43.67,106.9692,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,30,min,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) ,108454,2-Chloro-5-hydroxyphenylglycine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.5 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,514.67,uV,47.85,117.2081,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,30,min,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) ,108455,2-Chloro-5-hydroxyphenylglycine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.02 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,587.83,uV,53.2,130.3129,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,30,min,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) ,108456,2-Chloro-5-hydroxyphenylglycine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (0.5 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,579,uV,50.99,124.8995,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,30,min,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) ,108457,2-Chloro-5-hydroxyphenylglycine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (1 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,11,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,44.02,uV,13.47,44.6749,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,2,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) ,108476,2-Chloro-5-hydroxyphenylglycine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-4.5 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,11,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,270.09,uV,34.35,113.9261,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,2,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) ,108477,2-Chloro-5-hydroxyphenylglycine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-2.5 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,11,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,334.55,uV,43.36,143.8089,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,2,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) ,108478,2-Chloro-5-hydroxyphenylglycine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.5 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,11,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,351.91,uV,47.74,158.3357,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,2,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) ,108479,2-Chloro-5-hydroxyphenylglycine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.02 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,11,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,389.91,uV,52.11,172.8293,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,2,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) ,108480,2-Chloro-5-hydroxyphenylglycine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (0.5 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,11,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,410.09,uV,45.37,150.4753,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,2,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) ,108481,2-Chloro-5-hydroxyphenylglycine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (1 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,71.98,uV,18.54,45.4135,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,10,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) ,108500,2-Chloro-5-hydroxyphenylglycine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-4.5 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,385.17,uV,61.99,151.8439,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,10,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) ,108501,2-Chloro-5-hydroxyphenylglycine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-2.5 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,429.5,uV,66.11,161.9358,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,10,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) ,108502,2-Chloro-5-hydroxyphenylglycine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.5 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,485.67,uV,73.15,179.1802,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,10,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) ,108503,2-Chloro-5-hydroxyphenylglycine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.02 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,511.83,uV,65.06,159.3638,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,10,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) ,108504,2-Chloro-5-hydroxyphenylglycine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (0.5 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003705,scotopic B wave amplitude of ERG waveform,,b-wave amplitude ERG,,605.83,uV,62.69,153.5585,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,10,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) ,108505,2-Chloro-5-hydroxyphenylglycine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (1 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,6.38,uV,1.4,3.4293,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,30,min,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) ,108440,2-Chloro-5-hydroxyphenylglycine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-4.5 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,25.21,uV,4.23,10.3613,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,30,min,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) ,108441,2-Chloro-5-hydroxyphenylglycine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-2.5 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,88.5,uV,12.52,30.6676,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,30,min,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) ,108442,2-Chloro-5-hydroxyphenylglycine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.5 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,155.28,uV,13.68,33.509,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,30,min,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) ,108443,2-Chloro-5-hydroxyphenylglycine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.02 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,201.67,uV,18.19,44.5562,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,30,min,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) ,108444,2-Chloro-5-hydroxyphenylglycine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (0.5 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,216.67,uV,19.46,47.6671,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,30,min,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) ,108445,2-Chloro-5-hydroxyphenylglycine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (1 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,11,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,5.17,uV,1.18,3.9136,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,2,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) ,108464,2-Chloro-5-hydroxyphenylglycine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-4.5 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,11,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,11.68,uV,2.42,8.0262,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,2,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) ,108465,2-Chloro-5-hydroxyphenylglycine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-2.5 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,11,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,71.37,uV,8.23,27.2958,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,2,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) ,108466,2-Chloro-5-hydroxyphenylglycine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.5 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,11,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,104.17,uV,12.63,41.889,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,2,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) ,108467,2-Chloro-5-hydroxyphenylglycine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.02 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,11,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,118.51,uV,12.59,41.7563,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,2,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) ,108468,2-Chloro-5-hydroxyphenylglycine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (0.5 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,11,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,137.5,uV,12.91,42.8176,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,2,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) ,108469,2-Chloro-5-hydroxyphenylglycine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (1 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,15.46,uV,4.1,10.0429,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,10,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) ,108488,2-Chloro-5-hydroxyphenylglycine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-4.5 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,24.73,uV,6.11,14.9664,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,10,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) ,108489,2-Chloro-5-hydroxyphenylglycine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-2.5 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,80.6,uV,11.3,27.6792,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,10,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) ,108490,2-Chloro-5-hydroxyphenylglycine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.5 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,119.33,uV,19.43,47.5936,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,10,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) ,108491,2-Chloro-5-hydroxyphenylglycine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (-0.02 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,166.85,uV,19.57,47.9365,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,10,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) ,108492,2-Chloro-5-hydroxyphenylglycine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (0.5 log(cd x m/s2)) 3123,"Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z.",rod electrophysiology trait,,RS:0000656,RCS-rdy+ p+/LavRrrc,both,0 days,6,,CMO:0003706,scotopic A wave amplitude of ERG waveform,,a-wave amplitude ERG,,188.33,uV,15.56,38.1141,MMO:0000616,electroretinography,cornea,0.0,CHPG,subretinal injection,10,days,2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) ,108493,2-Chloro-5-hydroxyphenylglycine (200 umol) ,controlled exposure to darkness (for 12 hours),visible light stimulus (1 log(cd x m/s2))